Promising clopidogrel analogs may overcome clopidogrel resistance: 2025 update

Area of Science:

• Pharmacology
• Medicinal Chemistry
• Cardiovascular Medicine

Background:

• Clopidogrel is a vital antiplatelet medication recommended by the WHO.
• Patient resistance to clopidogrel limits its effectiveness in certain individuals.
• Developing improved antiplatelet agents is crucial for cardiovascular disease management.

Purpose of the Study:

• To systematically review novel clopidogrel analogs.
• To evaluate the preclinical and clinical properties of these analogs.
• To understand the scientific strategies behind their design for enhanced efficacy.

Main Methods:

• Focus on enhancing metabolic activation to increase active thiol metabolites (H4).
• Design and synthesis of analogs bypassing cytochrome P450 activation (e.g., DT-678, evategrel, vicagrel).
• Investigation of shared metabolites (2-oxo-clopidogrel) and deuterated compounds.

Main Results:

• DT-678 releases H4 via GSH, bypassing CYP450.
• Evategrel is converted to H4 by esterase hydrolysis.
• Vicagrel and other analogs (tipidogrel, compound 6b, PLD-301, W-1) utilize similar strategies, improving H4 formation.
• Deuterated clopidogrel and vicagrel enhance hepatic H4 production.

Conclusions:

• Novel clopidogrel analogs demonstrate promising antiplatelet activity, surpassing clopidogrel.
• DT-678 and evategrel are leading candidates to overcome clopidogrel resistance due to improved efficacy and safety.
• These advancements offer potential solutions for patients unresponsive to current antiplatelet therapies.